Study of ribosomal vaccine against experimental Staphylococcal skin infection in rabbit

Il s’agit d'un vaccin constitué d’une partie d'ARN ribosomal de Sta phylococcus (souche humaine de St. aureus, St. epidermidis) et d’une partie et demie environ de protéoglycanes membranal res de Klebsiella {Kl. pneumoniae, biotype a, non pathogène). La vaccination par voie sous-cutanée, deux fois à 15 jours d'intervalle, à la dose de 12,5 mcg (ARNr + protéoglycanes) protège le lapin contre une infection expérimentale, pratiquée 3 semaines après la dernière vaccina tion, par voie intradermique avec une souche pathogène de St. aureus isolée chez le lapin. La protection est appréciée par la réduction (76 %) et par la diminution de la nécrose de la surface réagissante cutanée en comparaison des témoins. La nature de la protection est ensuite discutée ainsi que le mécanisme général d’action des vaccins ribosomaux.The vaccine is composed of one part of Staphylococcus ribosomal RNA (human strains of St. aureus, St. epidermidis) and approximately of one part and half of Klebsiella glycoproteins membranes (Kl. pneumoniae, biotype a, apathogen). 12,5 meg of the vaccine (rRNA + glycoproteins membranes) are injected subcutaneously to each rabbit at 15 days-intervals. The challenge is performed three weeks later, after the second vaccination, by the intra- dermal injection of live pathogen Staphylococcus aureus strain isolated from rabbit. The protection is appreciated by the reduction (76 %) of the surface area of the lesions and by the diminution of the necrosis in comparison with the controls. The nature of the protection is discussed and the general mechanism activity of the ribosomal vaccines

Study of ribosomal vaccine against experimental Staphylococcal skin infection in rabbit

Il s’agit d'un vaccin constitué d’une partie d'ARN ribosomal de Sta phylococcus (souche humaine de St. aureus, St. epidermidis) et d’une partie et demie environ de protéoglycanes membranal res de Klebsiella {Kl. pneumoniae, biotype a, non pathogène). La vaccination par voie sous-cutanée, deux fois à 15 jours d'intervalle, à la dose de 12,5 mcg (ARNr + protéoglycanes) protège le lapin contre une infection expérimentale, pratiquée 3 semaines après la dernière vaccina tion, par voie intradermique avec une souche pathogène de St. aureus isolée chez le lapin. La protection est appréciée par la réduction (76 %) et par la diminution de la nécrose de la surface réagissante cutanée en comparaison des témoins. La nature de la protection est ensuite discutée ainsi que le mécanisme général d’action des vaccins ribosomaux.The vaccine is composed of one part of Staphylococcus ribosomal RNA (human strains of St. aureus, St. epidermidis) and approximately of one part and half of Klebsiella glycoproteins membranes (Kl. pneumoniae, biotype a, apathogen). 12,5 meg of the vaccine (rRNA + glycoproteins membranes) are injected subcutaneously to each rabbit at 15 days-intervals. The challenge is performed three weeks later, after the second vaccination, by the intra- dermal injection of live pathogen Staphylococcus aureus strain isolated from rabbit. The protection is appreciated by the reduction (76 %) of the surface area of the lesions and by the diminution of the necrosis in comparison with the controls. The nature of the protection is discussed and the general mechanism activity of the ribosomal vaccines

In vitro cell activating properties of the composite ribosomal vaccine D53

D53 (RibomuntyR) is a composite vaccine made of immunogenic ribosomes from 4 bacterial species (Klebsiella pneumoniae, Haemophilus influenzae, Streptococcus pyogenes and Streptococcus pneumoniae) associated with a membrane proteoglycan from a non encapsulated strain of Klebsiella pneumoniae. D53 is a potent inducer of interleukin-1 production by mouse BALB/c spleen cells as shown by the C3H/HeJ thymocyte co-stimulation assay. Furthermore D53 triggers DNA synthesis by mouse spleen cells and induces the maturation of B lymphocytes into immunoglobulin secreting cells. Polyclonal B cell activation by D53 was readily achieved in the C3H/HeJ strain which is deficient in its response to E. coli lipopolysaccharide. The proliferative response to D53 was abrogated by removal of B cells from the spleen cell suspension, but it was not altered after depletion of T cells or adherent cells. D53 induced polyclonal B cell activation of spleen cells from athymic nude mice and from CBA/N mice. Each component of D53 induced polyclona B cell activation except ribosomes from Streptococcus pneumoniae. Each triggered Interleukin-1 synthesis except ribosomes from Klebsiella penumoniae. These in vitro properties may account for some of the in vivo immunostimulating properties of this composite vaccine